Risk categories and refractory CLL in the era of chemoimmunotherapy

Blood

Volumn 119, Issue 18, 2012, Pages 4101-4107

  Zenz, Thorsten ^a,b   Gribben, John G ^c   Hallek, Michael ^d   Döhner, Hartmut ^e   Keating, Michael J ^f   Stilgenbauer, Stephan ^e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLASSIFICATION ALGORITHM; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; GENE LOSS; GENE MUTATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCHEMOTHERAPY; IMMUNOGLOBULIN HEAVY CHAIN GENE; LEUKEMIA RELAPSE; LOW RISK POPULATION; MODEL; ONCOGENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84860773361     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-312421     Document Type: Review

References (63)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
2. Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187-197.
3. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood. 2006;107(4):1276-1283. (Pubitemid 43242359)
4. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
5. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
6. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
7. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
8. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11): 3016-3024.
9. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet. 2007;370(9583):230-239. (Pubitemid 47069536)
10. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107(3):885-891. (Pubitemid 43156283)
11. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007; 25(7):793-798. (Pubitemid 350002879)
12. Dreger P, Döhner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438-2447.
13. Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):781.
14. Zenz T, Busch R, Fink A, et al. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: Results from the CLL8 Trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2427.
15. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009;115(13):2824-2836.
16. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood. 2002;99(10):3554-3561. (Pubitemid 34534522)
17. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia [abstract]. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488.
18. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2): 219-234.
20. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
21. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 1977;50(6):1049-1059. (Pubitemid 8245208)
22. Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O. Guidelines for protocol studies in chronic lymphocytic leukemia. Am J Hematol. 1978;4(4):343-358. (Pubitemid 9066769)
23. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-3391.
24. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988;29(3):152-163.
25. International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989;110(3):236-238.
26. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
27. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia. 2007;21(1):12-17. (Pubitemid 44921829)
28. Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010;95(10):1705-1712.
29. Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009;113(14):3168-3171.
30. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): The Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044-2050.
31. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
32. Bö ttcher S, Stilgenbauer S, Busch R, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia. 2009;23(11): 2007-2017.
33. Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3428.
34. Bö ttcher S, Fischer K, Stilgenbauer S, et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab: A prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):326.
35. Bö ttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 Trial. J Clin Oncol. 2012;30(9):980-988.
36. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27(27):4578-4584.
37. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405-411. (Pubitemid 46105933)
38. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in firstline therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):205.
39. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799-804. (Pubitemid 350010635)
40. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437-443. (Pubitemid 46655595)
41. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103(9):3278-3281. (Pubitemid 38525651)
42. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85(6): 1580-1589.
43. Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT In CLL with 17p-or refractory to fludarabine: Interim analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116(21):920.
44. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589-2597.
45. Zenz T, Hoth P, Busch R, et al. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):1267.
46. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
47. Stilgenbauer S, Eichhorst BF, Busch R, et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC): Comprehensive analysis of the CLL4 trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):2089.
48. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: The M. D. Anderson and Mayo Clinic experience. Blood. 2009;114(5):957-964.
49. Fischer K, Cramer P, Busch R, et al. Bandamustine combined with rituscimab in patients with relapsed and/or refractory chronic lymphocytic leukemia multicenter phase 2 trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29(26):3559-3566.
50. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
51. Mohr J, Helfrich H, Fuge M, et al. DNA damageinduced transcriptional program in CLL: Biological and diagnostic implications for functional p53 testing. Blood. 2011;117(5):1622-1632.
52. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47-52.
53. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
54. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood. 2011;118(26): 6904-6908.
55. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012; 119(2):521-529.
56. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
57. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23(1):212-214.
58. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25(9):1114-1120. (Pubitemid 46596764)
59. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
60. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009;2009:602-609.
61. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008; 26(31):5094-5100.
62. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623.
63. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384.